Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes

Metabolism: Clinical and Experimental

Volumn 62, Issue 9, 2013, Pages 1330-1339

  Gastaldelli, Amalia ^a   Nauck, Michael A ^b   Balena, Raffaella ^c,d  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b DIABETESZENTRUM BAD LAUTERBERG   (Germany)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

GLP 1 analog pancreatic function Mixed meal tolerance test Postprandial glucose Postprandial insulin Postprandial glucagon

Indexed keywords

GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PLACEBO; TASPOGLUTIDE;

ADULT; AGED; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; ENDOCRINE PANCREAS FUNCTION TEST; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MIXED MEAL TOLERANCE TEST; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; PANCREAS FUNCTION; PANCREAS ISLET BETA CELL; PHASE 2 CLINICAL TRIAL; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

EID: 84883179637     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2013.05.001     Document Type: Article

References (43)

1. E. Sebokova, A.D. Christ, and H. Wang Taspoglutide, an analog of human glucagon-like peptide-1 with enhanced stability and in vivo potency Endocrinology 151 6 2010 2474 2482
2. C. Kapitza, T. Heise, and P. Birman Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type 2 diabetes Diabet Med 26 11 2009 1156 1164
3. M.A. Nauck, R.E. Ratner, and C. Kapitza Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study Diabetes Care 32 7 2009 1237 1243
4. R.R. Henry, S. Mudaliar, and L. Kanitra Efficacy and safety of taspoglutide in patients with type 2 diabetes inadequately controlled with metformin plus pioglitazone over 24 weeks: T-Emerge 3 trial J Clin Endocrinol Metab 97 7 2012 2370 2379
5. P. Hollander, B. Lasko, and A.H. Barnett Effects of taspoglutide on glycemic control and body weight in obese patients with type 2 diabetes (T-emerge 7 study) Obesity 21 2 2013 238 247
6. M. Nauck, E. Horton, and M. Andjelkovic Taspoglutide, a once-weekly glucagon-like peptide 1 analogue, vs. insulin glargine titrated to target in patients with type 2 diabetes: an open-label randomized trial Diabet Med 30 1 2013 109 113
7. R.E. Pratley, D. Urosevic, and M. Boldrin Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with type 2 diabetes uncontrolled with sulphonylurea or sulphonylurea-metformin therapy: a randomized, double-blind study (T-emerge 6) Diabetes Obes Metab 15 3 2013 234 240
8. R.M. Bergenstal, A. Forti, and J.L. Chiasson Efficacy and safety of taspoglutide versus sitagliptin for type 2 diabetes mellitus (T-emerge 4 trial) Diabet Ther 3 1 2012 13
9. I. Raz, V. Fonseca, and M. Kipnes Efficacy and safety of taspoglutide monotherapy in drug-naive type 2 diabetic patients after 24 weeks of treatment: results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1) Diabetes Care 35 3 2012 485 487
10. J. Rosenstock, B. Balas, and B. Charbonnel The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial Diabetes Care 36 3 2013 498 504
11. S. Madsbad, U. Kielgast, and M. Asmar An overview of once-weekly glucagon-like peptide-1 receptor agonists - available efficacy and safety data and perspectives for the future Diabetes Obes Metab 13 5 2011 394 407
12. R.A. DeFronzo, T. Okerson, and P. Viswanathan Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study Curr Med Res Opin 24 10 2008 2943 2952
13. C.M. Perry Liraglutide: a review of its use in the management of type 2 diabetes mellitus Drugs 71 17 2011 2347 2373
14. M. Christensen, F.K. Knop, and T. Vilsboll Lixisenatide for type 2 diabetes mellitus Expert Opin Investig Drugs 20 4 2011 549 557
15. R. Gentilella, C. Bianchi, and A. Rossi Exenatide: a review from pharmacology to clinical practice Diabetes Obes Metab 11 6 2009 544 556
16. O.G. Kolterman, D.D. Kim, and L. Shen Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus Am J Health Syst Pharm 62 2 2005 173 181
17. C.B. Juhl, M. Hollingdal, and J. Sturis Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes Diabetes 51 2 2002 424 429
18. J. Larsen, B. Hylleberg, and K. Ng Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment Diabetes Care 24 8 2001 1416 1421
19. M. Zander, S. Madsbad, and J.L. Madsen Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study Lancet 359 9309 2002 824 830
20. J.B. Buse, J. Rosenstock, and G. Sesti Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) Lancet 374 9683 2009 39 47
21. D.J. Drucker, J.B. Buse, and K. Taylor Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study Lancet 372 9645 2008 1240 1250
22. D.J. Drucker, and M.A. Nauck The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 368 9548 2006 1696 1705
23. E. Van Cauter, F. Mestrez, and J. Sturis Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance Diabetes 41 3 1992 368 377
24. A. Gastaldelli, E. Ferrannini, and Y. Miyazaki Thiazolidinediones improve β-cell function in type 2 diabetic patients Am J Physiol Endocrinol Metab 292 3 2007 E871 E883
25. A. Starke, S. Grundy, and J.D. McGarry Correction of hyperglycemia with phloridzin restores the glucagon response to glucose in insulin-deficient dogs: implications for human diabetes Proc Natl Acad Sci U S A 82 5 1985 1544 1546
26. R.H. Unger Glucagon and the insulin: glucagon ratio in diabetes and other catabolic illnesses Diabetes 20 12 1971 834 838
27. A. Mari, G. Pacini, and E. Murphy A model-based method for assessing insulin sensitivity from the oral glucose tolerance test Diabetes Care 24 3 2001 539 548
28. A. Gastaldelli, E. Ferrannini, and Y. Miyazaki Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study Diabetologia 47 1 2004 31 39
29. T. Vilsbøll, B. Brock, and H. Perrild Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus Diabet Med 25 2 2008 152 156
30. D. Kim, L. MacConell, and D. Zhuang Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes Diabetes Care 30 6 2007 1487 1493
31. M.S. Fineman, B.B. Cirincione, and D. Maggs GLP-1 based therapies: differential effects on fasting and postprandial glucose Diabetes Obes Metab 14 8 2012 675 688
32. M.A. Nauck, U. Niedereichholz, and R. Ettler Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans Am J Physiol 273 5 Pt 1 1997 E981 E988
33. L.L. Kjems, J.J. Holst, and A. Vølund The influence of GLP-1 on glucose-stimulated insulin secretion: effects on β-cell sensitivity in type 2 and nondiabetic subjects Diabetes 52 2 2003 380 386
34. D. Russell-Jones, R.M. Cuddihy, and M. Hanefeld Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study Diabetes Care 35 2 2012 252 258
35. M.C. Bunck, A. Corner, and B. Eliasson Effects of exenatide on measures of beta-cell function after 3 years in metformin-treated patients with type 2 diabetes Diabetes Care 34 9 2011 2041 2047
36. K.B. Degn, C.B. Juhl, and J. Sturis One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes Diabetes 53 5 2004 1187 1194
37. E. Ferrannini, A. Gastaldelli, and Y. Miyazaki beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis J Clin Endocrinol Metab 90 1 2005 493 500
38. E. Cersosimo, A. Gastaldelli, and A. Cervera Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects J Clin Endocrinol Metab 96 6 2011 1763 1770
39. R.H. Unger, and L. Orci Physiology and pathophysiology of glucagon Physiol Rev 56 4 1976 778 826
40. B.R. Gedulin, S.E. Nikoulina, and P.A. Smith Exenatide (exendin-4) improves insulin sensitivity and β-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight Endocrinology 146 4 2005 2069 2076
41. G. Svegliati-Baroni, S. Saccomanno, and C. Rychlicki Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis Liver Int 31 9 2011 1285 1297
42. M. Seghieri, E. Rebelos, and A. Gastaldelli Direct effect of GLP-1 infusion on endogenous glucose production in humans Diabetologia 56 1 2013 156 161
43. E. Muscelli, A. Casolaro, and A. Gastaldelli Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes J Clin Endocrinol Metab 97 8 2012 2818 2826